At-A-Glance

Important information about REVLIMID® (lenalidomide) and the REVLIMID Risk Evaluation and Mitigation Strategy (REMS)™ program

- REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy.
- To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called “REVLIMID REMS™” (formerly known as the RevAssist® program).
- Only prescribers and pharmacies certified by the REVLIMID REMS™ program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS™ program.
- Information about REVLIMID and the REVLIMID REMS™ program can be obtained by visiting www.CelgeneRiskManagement.com, or calling the Celgene Customer Care Center toll-free at 1-888-423-5436.

For more information about REVLIMID and the REVLIMID REMS™ program, please visit www.CelgeneRiskManagement.com, or call the Celgene Customer Care Center at 1-888-423-5436.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.
Initial prescription (for all patients unless otherwise noted)

1. For females of reproductive potential, obtain 2 negative pregnancy tests sensitive to at least 50 mIU/mL, even if continuous abstinence is the chosen method of birth control. One test must be obtained 10 to 14 days and one test within 24 hours prior to writing an initial prescription for REVLIMID® (lenalidomide).
2. Provide mandatory counseling: no drug sharing, no blood or sperm donation, and appropriate contraceptive use. Patients should be instructed to not extensively handle or open REVLIMID capsules.
3. Obtain, review, and complete the REVLIMID® (lenalidomide) Patient-Physician Agreement Form online by visiting www.CelgeneRiskManagement.com, accessing the Celgene REMS mobile app, using the CD-ROM software, or by calling the Celgene Customer Care Center for assistance at 1-888-423-5436.
   • Males (adults and children)
   • Females of reproductive potential include all females who are menstruating, amenorrheic from previous medical treatments, under 50 years of age, and/or perimenopausal, and do not qualify for the females not of reproductive potential category
   • Females not of reproductive potential include females who have been in natural menopause for at least 24 consecutive months, or who have had a hysterectomy and/or bilateral oophorectomy, or female children who have not started menstruating
4. Send the completed and signed REVLIMID® (lenalidomide) Patient-Physician Agreement Form online through www.CelgeneRiskManagement.com, the Celgene REMS mobile app, or to the Celgene Customer Care Center by faxing to 1-888-432-9325.
5. Instruct female patients to complete a brief initial mandatory confidential survey by visiting www.CelgeneRiskManagement.com, accessing the Celgene REMS mobile app, or calling 1-888-423-5436, prior to prescriber obtaining an authorization number.
   • Males do not need to complete the initial survey
6. Complete a prescriber brief mandatory confidential survey by visiting www.CelgeneRiskManagement.com, accessing the Celgene REMS mobile app, or calling the Celgene Customer Care Center at 1-888-423-5436, for every patient before each prescription is written.
   • You will need to enter the following information:
     - Prescriber’s identification number
     - Patient’s identification number
     - Date and result of patient’s last pregnancy test(s) (if applicable); valid only for 7 days from date of last pregnancy test
     - Average daily dose
     - Total number of days supplied (cannot exceed 28 days)
7. An authorization number will be issued upon completion of the survey and must be written along with the patient risk category on the prescription. Authorization numbers are valid for 7 days from date of last pregnancy test for females of reproductive potential and 30 days from the date it is issued for all other patients. No automatic refills or telephone prescriptions are permitted.
8. Send the prescription to a certified pharmacy.
Subsequent prescriptions (for all patients unless otherwise noted)

1. For females of reproductive potential, obtain scheduled pregnancy tests weekly during the first 4 weeks of use; then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks.

2. Provide mandatory counseling: no drug sharing, no blood or sperm donation, and appropriate contraceptive use. Patients should be instructed to not extensively handle or open REVLIMID capsules.

3. Instruct patient to complete a brief mandatory confidential survey as scheduled, prior to prescriber obtaining an authorization number and filling the prescription.
   - Monthly:
     - Males (adults and children)
     - Females of reproductive potential (adults and children)
     - Female children not of reproductive potential
   - Every 6 months:
     - Adult females not of reproductive potential

4. Complete a prescriber brief mandatory confidential survey by visiting www.CelgeneRiskManagement.com, accessing the Celgene REMS mobile app, or calling the Celgene Customer Care Center at 1-888-423-5436, for every patient before each prescription is written.
   - You will need to enter the following information:
     - Prescriber’s identification number
     - Patient’s identification number
     - Date and result of patient’s last pregnancy test(s) (if applicable); valid only for 7 days from date of last pregnancy test
     - Average daily dose
     - Total number of days supplied (cannot exceed 28 days)

5. An authorization number will be issued upon completion of the survey and must be written along with the patient risk category on the prescription. Authorization numbers are valid for 7 days from date of last pregnancy test for females of reproductive potential and 30 days from the date it is issued for all other patients. No automatic refills or telephone prescriptions are permitted.

6. Send the prescription to a certified pharmacy.

REVLIMID® is a registered trademark of Celgene Corporation. REVLIMID REMS™ is a trademark of Celgene Corporation.

©2014 Celgene Corporation 10/14 REMS-REV14575